

## **Medication Assurance Program**

If you are enrolled in a commercial health benefit plan provided by or administered by Excellus BlueCross BlueShield where the Medication Assurance Program benefit applies:

The following drugs were preliminarily approved through the accelerated approval pathway by the U.S. Food and Drug Association (FDA). At this time, these drugs have unconfirmed clinical benefit and **will not be covered under prescription drug benefits or medical benefits**. Drug manufacturers of the drugs listed below are required to conduct clinical studies to prove clinical benefit in order to achieve traditional/final FDA approval. These drugs will continue to be monitored and remain uncovered until clinical benefits are proven and confirmed by criteria set forth by the FDA.

- ADUHELM\*
- ALIQOPA\*
- AMONDYS 45\*
- AMTAGVI\*
- ARIKAYCE
- BELEODAO\*
- COLUMVI\*
- DANYELZA\*
- ELEVIDYS\*
- ELREXFIO\*
- EPKINLY\*
- EXONDYS 51\*
- FILSPARI
- FOLOTYN\*
- IMDELLTRA\*
- IOIRVO
- JAYPIRCA
- LUMAKRAS
- LUNSUMIO\*
- LYTGOBI
- MONJUVI\*
- NORTHERA
- OCALIVA
- OJEMDA
- OXBRYTA

- PRALATREXATE\*
- OALSODY\*
- REZDIFFRA
- SKYSONA\*
- TALVEY\*
- TAZVERIK
- TECVAYLI\*
- VILTEPSO\*
- VONJO
- VOXZOGO
- VYONDYS 53\*
- ZEPZELCA\*
- ZYNLONTA\*
- ZYNYZ\*

If you have questions regarding your drug coverage, please contact customer care at the number on the back of your card.

<sup>\*</sup>Medical benefit drug